NEJM publishes encouraging study data on Genmab's daratumumab monotherapy in multiple myeloma

27 August 2015
2019_biotech_test_vial_discovery_big

The New England Journal of Medicine has published the full dataset from Danish biotech company Genmab (OMX: GEN) on its Phase I/II study with daratumumab monotherapy in relapsed or refractory multiple myeloma.

The data showed a 36% response rate in the 16 mg/kg group in part 2 of the study, with responses that deepened over time, and 65% of patients in this group that responded to treatment were progression-free twelve months following the start of treatment.  Patients receiving 16mg/kg had a median of four prior lines of therapy, and 64% of these patients were refractory to protease inhibitors and immunomodulatory drugs, which are the current standard of care treatments for multiple myeloma.

The 16mg/kg dose was chosen as the dose to be used in future daratumumab trials. The drug is being developed by Janssen Biotech, a unit of Johnson & Johnson (NYSE: JNJ), under an exclusive license from Genmab.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology